SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-309571
Filing Date
2020-12-03
Accepted
2020-12-03 16:33:00
Documents
8
Period of Report
2020-12-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d860249d8k.htm 8-K 23539
2 EX-1.1 d860249dex11.htm EX-1.1 230714
3 EX-5.1 d860249dex51.htm EX-5.1 8037
4 EX-99.1 d860249dex991.htm EX-99.1 14342
5 EX-99.2 d860249dex992.htm EX-99.2 14450
6 GRAPHIC g860249g1203112259575.jpg GRAPHIC 3207
7 GRAPHIC g860249g1203112640615.jpg GRAPHIC 2477
8 GRAPHIC g860249g1203112739538.jpg GRAPHIC 2477
  Complete submission text file 0001193125-20-309571.txt   304009
Mailing Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462
Business Address ONE NEWTON EXECUTIVE PARK SUITE 202 NEWTON MA 02462 617-467-4577
Allena Pharmaceuticals, Inc. (Filer) CIK: 0001624658 (see all company filings)

IRS No.: 452729920 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38268 | Film No.: 201367322
SIC: 2836 Biological Products, (No Diagnostic Substances)